文献速递淋巴瘤造血干细胞移植与细胞治疗

原发中枢神经系统淋巴瘤大型队列巩固治疗模式的演变与结局

Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphoma.
PubMed 文献 · Blood Adv · 2024-01-01

该研究纳入1983至2020年559例原发中枢神经系统淋巴瘤患者,其中385例(69%)接受巩固治疗,分析全脑放疗、非清髓化疗和自体造血干细胞移植的使用趋势及生存结局。全脑放疗使用下降而移植和非清髓化疗上升,校正后各巩固策略间无显著生存差异,非清髓化疗使用增多但无进展生存趋势较差。

要点

  • 全脑放疗使用从1990年代61%降至2010年代12%,自体移植从4%升至32%,非清髓化疗从27%升至52%。
  • 对诱导部分缓解者较少接受自体移植(OR 0.36,P=0.02)。
  • 校正后各巩固策略间无显著生存差异,非清髓化疗有PFS较差的趋势。

核心结论

  • 非清髓化疗正越来越多地替代减剂量全脑放疗,尽管无进展生存有较差趋势。
  • 对不适合自体造血干细胞移植的患者可考虑减剂量全脑放疗。

研究设计与样本

  • 回顾性队列研究,纳入1983至2020年559例原发中枢神经系统淋巴瘤患者,其中385例(69%)接受巩固治疗。
  • 按年代和纪念斯隆凯特琳癌症中心递归 partitioning 分析(RPA)分类分层,采用多项逻辑回归、比例风险模型分析。

主要发现

  • 中位随访7.4年,中位总生存5.7年。
  • 全脑放疗使用从1990年代61%降至2010年代12%,自体移植从4%升至32%,非清髓化疗从27%升至52%。
  • 与RPA 1相比,RPA 2更可能接受非清髓化疗;诱导部分缓解者较少接受自体移植(OR 0.36,P=0.02)。
  • 351例巩固后完全缓解者中,仅含利妥昔单抗、甲氨蝶呤、丙卡巴肼和长春新碱的诱导方案与改善无进展生存相关(HR 0.5,P=0.006)。
  • RPA 1中,自体移植或减剂量全脑放疗的中位PFS和OS均未达到,而非清髓化疗分别为2.5年和13.0年;RPA 3中,减剂量全脑放疗后中位PFS和OS分别为4.6年和10年,非清髓化疗分别为1.7年和4.4年。

关键数值与推荐

  • 减剂量全脑放疗定义为≤24 Gy,标准剂量为>24 Gy。
  • 巩固方式包括全脑放疗、阿糖胞苷、非清髓化疗或自体造血干细胞移植。

临床怎么用

  • 作者认为,对不适合自体造血干细胞移植的患者可考虑减剂量全脑放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Consolidation for primary central nervous system lymphoma (PCNSL) after induction chemoimmunotherapy include whole-brain radiotherapy (WBRT; ≤24 Gy reduced-dose [RD], >24 Gy standard-dose) and cytarabine, nonmyeloablative chemotherapy (NMC), or autologous hematopoietic cell transplantation (AHCT). Comparative outcomes are lacking. Outcomes from 1983-2020 were stratified by decade and Memorial Sloan Kettering Cancer Center recursive partitioning analysis (RPA) class. Clinicodemographic associations were analyzed by multinomial logistic regression. Progression-free survival (PFS) and overall survival (OS) were analyzed by proportional hazards. Of 559 patients, 385 (69%) were consolidated. Median follow-up and OS were 7.4 and 5.7 years, respectively. WBRT use declined (61% (1990s) vs 12% (2010s)), whereas AHCT (4% (1990s) vs 32% (2010s)) and NMC (27% (1990s) vs 52% (2010s)) rose. Compared with RPA 1, RPA 2 was more likely to receive NMC. Those with partial response to induction were less likely to receive AHCT (odds ratio, 0.36; P = .02). Among 351 with complete response to consolidation, only receipt of rituximab, methotrexate, procarbazine, and vincristine induction was associated with improved PFS (hazard ratio, 0.5; P = .006). Among RPA 1, median PFS and OS were not reached for AHCT or RD-WBRT, vs 2.5 and 13.0 years, respectively, after NMC. Among RPA class 3, median PFS and OS after RD-WBRT were 4.6 and 10 years, vs 1.7 and 4.4 years after NMC. No significant adjusted survival differences were seen across consolidation strategies. NMC is increasingly used in lieu of RD-WBRT despite a trend toward less favorable PFS. RD-WBRT can be considered in patients ineligible for AHCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tringale KR, Scordo M, Yahalom J, et al. Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphoma. Blood Adv. 2024. PMID: 39167801. doi:10.1182/bloodadvances.2024013780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。